Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.90
ETRM's Cash to Debt is ranked higher than
74% of the 479 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ETRM: 3.90 )
ETRM' s 10-Year Cash to Debt Range
Min: 1.29   Max: No Debt
Current: 3.9

F-Score: 2
Z-Score: -24.17
M-Score: -5.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -205.04
ETRM's ROE (%) is ranked lower than
55% of the 448 Companies
in the Global Medical Devices industry.

( Industry Median: 5.76 vs. ETRM: -205.04 )
ETRM' s 10-Year ROE (%) Range
Min: -1135.7   Max: -77.38
Current: -205.04

-1135.7
-77.38
ROA (%) -117.04
ETRM's ROA (%) is ranked lower than
54% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. ETRM: -117.04 )
ETRM' s 10-Year ROA (%) Range
Min: -962.06   Max: -60.09
Current: -117.04

-962.06
-60.09
ROC (Joel Greenblatt) (%) -5020.20
ETRM's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 9.33 vs. ETRM: -5020.20 )
ETRM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4833.43   Max: -578.16
Current: -5020.2

-4833.43
-578.16
EBITDA Growth (3Y)(%) -23.60
ETRM's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. ETRM: -23.60 )
ETRM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -23.6
Current: -23.6

EPS Growth (3Y)(%) -23.20
ETRM's EPS Growth (3Y)(%) is ranked higher than
55% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. ETRM: -23.20 )
ETRM' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.1   Max: 41.9
Current: -23.2

-69.1
41.9
» ETRM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ETRM Guru Trades in Q1 2014

Chuck Royce 1,285,000 sh (unchged)
» More
Q2 2014

ETRM Guru Trades in Q2 2014

Chuck Royce 1,060,000 sh (-17.51%)
» More
Q3 2014

ETRM Guru Trades in Q3 2014

Chuck Royce 648,600 sh (-38.81%)
» More
Q4 2014

ETRM Guru Trades in Q4 2014

Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ETRM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.90
ETRM's P/B is ranked lower than
54% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 4.25 vs. ETRM: 9.90 )
ETRM' s 10-Year P/B Range
Min: 3.02   Max: 11.1
Current: 9.9

3.02
11.1
EV-to-EBIT -2.57
ETRM's EV-to-EBIT is ranked higher than
55% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 75.34 vs. ETRM: -2.57 )
ETRM' s 10-Year EV-to-EBIT Range
Min: -4.6   Max: -0.9
Current: -2.57

-4.6
-0.9
Current Ratio 1.69
ETRM's Current Ratio is ranked higher than
65% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.48 vs. ETRM: 1.69 )
ETRM' s 10-Year Current Ratio Range
Min: 1.69   Max: 9.46
Current: 1.69

1.69
9.46
Quick Ratio 1.56
ETRM's Quick Ratio is ranked higher than
71% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 1.88 vs. ETRM: 1.56 )
ETRM' s 10-Year Quick Ratio Range
Min: 1.56   Max: 9.46
Current: 1.56

1.56
9.46

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.50
ETRM's Price/Net Cash is ranked higher than
91% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ETRM: 16.50 )
ETRM' s 10-Year Price/Net Cash Range
Min: 2.61   Max: 23.67
Current: 16.5

2.61
23.67
Price/Net Current Asset Value 16.50
ETRM's Price/Net Current Asset Value is ranked higher than
86% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ETRM: 16.50 )
ETRM' s 10-Year Price/Net Current Asset Value Range
Min: 2.48   Max: 17.75
Current: 16.5

2.48
17.75
Price/Tangible Book 9.90
ETRM's Price/Tangible Book is ranked higher than
58% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 7.75 vs. ETRM: 9.90 )
ETRM' s 10-Year Price/Tangible Book Range
Min: 1.42   Max: 44.22
Current: 9.9

1.42
44.22
Earnings Yield (Greenblatt) -39.70
ETRM's Earnings Yield (Greenblatt) is ranked lower than
59% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. ETRM: -39.70 )
ETRM' s 10-Year Earnings Yield (Greenblatt) Range
Min: -44   Max: 0
Current: -39.7

-44
0

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:BY8N.Germany,
EnteroMedics Inc was incorporated in Minnesota on December 19, 2002. The Company is a development stage medical device company with approvals to commercially launch its product in Australia, the European Economic Area and other countries that recognize the European CE Mark. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. Its proprietary neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Company has limited operating history and currently only has regulatory approval to sell its product in Australia, the European Economic Area and other countries that recognize the European CE Mark. Its initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company competes in the market for obesity treatment with surgical obesity procedures and various devices used to implement neurostimulation and gastric stimulation systems. Its competitors include: Abbott Labs, Roche, GlaxoSmithKline and Arena Pharmaceuticals, Inc. The Company's trademarks include: VBLOC, ENTEROMEDICS, MAESTRO, MAESTRO SYSTEM ORCHESTRATING OBESITY SOLUTIONS, VBLOC POWER TO CHOOSE and VBLOC POWER TO CHOOSE AND DESIGN are the subject of either a trademark registration or application for registration in Australia, Brazil, China, the European Community, India, Kuwait, Mexico, Saudi Arabia, Switzerland and the United Arab Emirates. The Company uses third parties to manufacture its Maestro System to minimize its capital investment, help control costs and take advantage of the expertise these third parties have in the large-scale production of medical devices. Its Maestro System is regulated by the FDA as a medical device under the Federal Food, Drug, and Cosmetic Act or FFDCA and the regulations promulgated under the FFDCA. Pursuant to the FFDCA, the FDA regulates the research, design, testing, manufacture, safety, labeling, storage, record keeping, advertising, sales and distribution, post-market adverse event reporting, production and advertising and promotion of medical devices in the United States.
» More Articles for ETRM

Headlines

Articles On GuruFocus.com
Canaccord Genuity Remains Bullish on EnteroMedics Following Q4 Earnings Feb 19 2015 
Analysts Are Bullish On EnteroMedics Following FDA Approval Of Obesity Treatment Jan 16 2015 
EnteroMedics Inc. Reports Operating Results (10-K) Mar 07 2011 
EnteroMedics Inc. Reports Operating Results (10-Q) Nov 08 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) Aug 06 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) May 07 2010 
EnteroMedics Inc. Reports Operating Results (10-Q) Nov 16 2009 
EnteroMedics Inc. Reports Operating Results (10-Q) Aug 07 2009 
EnteroMedics Inc. Reports Operating Results (10-Q) May 08 2009 
EnteroMedics Reports 2008 Year-End Financial Results Jan 30 2009 

More From Other Websites
ENTEROMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers Mar 13 2015
GSK's big bet: Tapping our body's electronics Mar 11 2015
EnteroMedics to Present at Upcoming Investor Conferences Feb 25 2015
EnteroMedics to Present at Upcoming Investor Conferences Feb 25 2015
EnteroMedics reports 4Q loss Feb 18 2015
EnteroMedics reports 4Q loss Feb 18 2015
EnteroMedics Reports Fourth Quarter 2014 Financial Results Feb 18 2015
Q4 2014 EnteroMedics Inc Earnings Release - Before Market Open Feb 18 2015
EnteroMedics Reports Fourth Quarter 2014 Financial Results Feb 18 2015
Shifts In Government Policy Create Potential Surge For Medical Device Leader Pressure Biosciences,... Feb 10 2015
ENTEROMEDICS INC Files SEC form 8-K, Other Events Feb 09 2015
EnteroMedics to Host Fourth Quarter 2014 Financial Results and Commercialization Update Conference... Feb 05 2015
EnteroMedics to Present at the 17th Annual BIO CEO & Investor Conference Jan 29 2015
Hunger game: FDA approves new obesity fighter Jan 16 2015
Obesity Device That Makes You Feel Full to Cost $15,000 Jan 14 2015
ENTEROMEDICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 14 2015
EnteroMedics Spikes Up 20% Following FDA Approval Of Neuroblocking Obesity Device Jan 14 2015
EnteroMedics Announces FDA Approval of VBLOC® Vagal Blocking Therapy for the Treatment of Obesity Jan 14 2015
Can The Uptrend Continue for EnteroMedics (ETRM)? Nov 20 2014
EnteroMedics to Participate at the 2014 Canaccord Genuity Medical Technology and Diagnostics Forum Nov 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK